• Veracyte, Inc. reported first-quarter 2026 results with revenue rising to US$139.07 million and net income to US$28.71 million, significantly ahead of the prior year and analyst expectations, and raised its full-year 2026 revenue guidance to a range of US$582 million–US$592 million.
• Alongside this financial strength, Veracyte is reinforcing the clinical footprint of its Decipher portfolio, with more than 15 new bladder and prostate cancer studies being presented at the 2026 American Urological Association meeting, underlining how genomic classifiers are being used to inform more personalized treatment decisions.
• We’ll now examine how Veracyte’s upgraded 2026 revenue guidance reshapes the earlier investment narrative and what it might mean for investors.

Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.

Veracyte Investment Narrative Recap

To own Veracyte, you need to believe that advanced genomic tests like Decipher and Afirma can keep gaining traction in cancer care while new products broaden the portfolio. The raised 2026 revenue guidance to US$582 million–US$592 million strengthens that thesis in the near term, but it does not eliminate the key risk that so much of today’s revenue is still concentrated in a few core assays.

The most relevant recent update here is Veracyte’s upgraded 2026 outlook following its first quarter, where revenue rose to US$139.07 million and net income to US$28.71 million, ahead of expectations. This stronger profitability gives the company more room to keep investing in launches like Prosigna and TruMRD, which are central to reducing product concentration risk and supporting the longer term growth story.

Yet even with these strong numbers, investors should be aware that growing pricing and reimbursement pressure on key tests could...

Veracyte's narrative projects $712.5 million revenue and $96.2 million earnings by 2029. This requires 11.3% yearly revenue growth and a $29.8 million earnings increase from $66.4 million today.

Uncover how Veracyte's forecasts yield a $47.00 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Before this earnings beat, the most optimistic analysts were already assuming Veracyte could reach about US$745 million of revenue and US$112 million of earnings by 2029, which is a much rosier path than consensus and leans heavily on faster MRD adoption and sustained high pricing. The latest results and guidance upgrade could support that view or prompt revisions in either direction, so it is worth weighing how confident you really are in those more aggressive assumptions.

Explore 4 other fair value estimates on Veracyte - why the stock might be worth as much as 33% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Veracyte research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Veracyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veracyte's overall financial health at a glance.

No Opportunity In Veracyte?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.